Impact of Convalescent Plasma Transfusion (CCP) In Patients With Previous Circulating Neutralizing Antibodies (nAb) to COVID-19
Authors:
- Ana Paula H YokoyamaAYAna Paula H Yokoyama
- Silvano WendelSilvano Wendel
- Carolina Bonet-BubCBCarolina Bonet-Bub
- Valeria F DutraVDValeria F Dutra
- Gabriela CandelariaGCGabriela Candelaria
- Araci M SakashitaASAraci M Sakashita
- Rafael Rahal Guaragna MachadoRMRafael Rahal Guaragna Machado
- Nelson HamerschlakNHNelson Hamerschlak
Preprint
Abstract
INTRODUCTION COVID-19 convalescent plasma (CCP) transfusion has emerged in the past months as an alternative approach to treat pneumonia cases of SARS-CoV-2. Current evidence regarding characteristics of the plasma product, the titer of neutralizing antibodies (nAbs) in the transfused units, time to onset of intervention, and impact of nAbs produced by the patient are limited and heterogeneous. MATERIAL AND METHODS We describe the preliminary results of 104 patients with severe pneumonia due to SARS-CoV-2 transfused with CCP at three medical centers in Brazil. All enrolled patients were transfused with doses between 200 mL through 600mL of ABO compatible CCP on days 0-2 after enrolment. Clinical parameters were monitored and nAbs titration was performed using the cytopathic effect-based virus neutralization test with SARS-CoV-2 (GenBank MT126808.1). RESULTS Forty-one patients achieved clinical improvement on day 14, and multivariable logistic regression showed that nAbs T (from CCP units transfused) (p= 0.001), nAbs P0 (on day of enrolment) (p=0.009) and use of other supportive therapies (pDISCUSSION/CONCLUSION Despite the study limitations, our data have shown an association between patients’ previously acquired nAbs and clinical outcomes. The potential value of timely administration of CCP transfusion before day 10 of disease onset was demonstrated and nAbsP0, but not nAbsT, were associated with ICU LOS, and duration of mechanical ventilation on the improvement of clinical outcomes was also demonstrated. In conclusion, we consider these data are useful parameters to guide future CPP transfusion strategies to COVID-19.Keywords
This publication has 36 references indexed in Scilit:
- The convalescent sera option for containing COVID-19Journal of Clinical Investigation, 2020
- Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2International Journal of Biological Sciences, 2020
- Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi ArabiaEmerging Infectious Diseases, 2016
- Data Analysis2016
- Evaluation of Convalescent Plasma for Ebola Virus Disease in GuineaNew England Journal of Medicine, 2016
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Hyperimmune IV Immunoglobulin TreatmentChest, 2013
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990